TradingView

Key facts: Merck KGaA to Buy Bio-Techne; Break Fees $576M/$230M

June 27, 2026 GMT+8 13:13 TradingView

Merck KGaA to buy Bio-Techne to boost lab‑tools, cell/gene therapy and precision‑medicine capabilities, aiming for scale as biotech funding slows and R&D spending is expected to re

Merck KGaA to buy Bio-Techne to boost lab‑tools, cell/gene therapy and precision‑medicine capabilities, aiming for scale as biotech funding slows and R&D spending is expected to recover
Merck KGaA would owe a $576.1M break fee to Bio-Techne if the merger ends under certain conditions; Bio-Techne would owe Merck $230.5M per the filing.